Thiopurine metabolite measurement leads to changes in management of inflammatory bowel disease

Internal Medicine Journal

Volumn 43, Issue 3, 2013, Pages 278-286

  Kennedy, N A ^a,b   Asser, T L ^b,d   Mountifield, R E ^b   Doogue, M P ^b,c   Andrews, J M ^e,f   Bampton, P A ^b,c  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b FLINDERS MEDICAL CENTRE   (Australia)

^c FLINDERS UNIVERSITY   (Australia)

^d UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^e ROYAL ADELAIDE HOSPITAL   (Australia)

^f UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

6 mercaptopurine; Azathioprine; Crohn disease; Drug monitoring; Ulcerative colitis

Indexed keywords

6 METHYLTHIOINOSINE; ALLOPURINOL; AZATHIOPRINE; DRUG METABOLITE; INFLIXIMAB; MERCAPTOPURINE; TIOGUANINE;

ADULT; ARTICLE; AUSTRALIA; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; ENTERITIS; FEMALE; HUMAN; LEUKOPENIA; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

6-MERCAPTOPURINE; ADULT; BIOLOGICAL MARKERS; DISEASE MANAGEMENT; FEMALE; GUANINE NUCLEOTIDES; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; THIONUCLEOTIDES;

EID: 84874353885     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2012.02936.x     Document Type: Article

References (39)

1. Bean RH. The treatment of chronic ulcerative colitis with 6-mercaptopurine. Med J Aust 1962; 49: 592-593.
2. Brooke B. Azathioprine for Crohn's disease. Lancet 1969; 294: 612-614.
3. Gearry RB, Barclay ML. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J Gastroenterol Hepatol 2005; 20: 1149-1157.
4. Dignass A, Van Assche G, Lindsay JO, Lémann M, Söderholm J, Colombel JF et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010; 4: 28-62.
5. Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011; 60: 571-607.
6. Travis SPL, Stange EF, Lémann M, Oresland T, Bemelman WA, Chowers Y et al. European evidence-based consensus on the management of ulcerative colitis: current management. J Crohns Colitis 2008; 2: 24-62.
7. Schütz E, Gummert J, Mohr FW, Armstrong VW, Oellerich M. Should 6-thioguanine nucleotides be monitored in heart transplant recipients given azathioprine? Ther Drug Monit 1996; 18: 228-233.
8. Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Théorêt Y et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 705-713.
9. Gardiner SJ, Gearry RB, Burt MJ, Ding SL, Barclay ML. Severe hepatotoxicity with high 6-methylmercaptopurine nucleotide concentrations after thiopurine dose escalation due to low 6-thioguanine nucleotides. Eur J Gastroenterol Hepatol 2008; 20: 1238-1242.
10. Achkar J-P, Stevens T, Easley K, Brzezinski A, Seidner D, Lashner B. Indicators of clinical response to treatment with six-mercaptopurine or azathioprine in patients with inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 339-345.
11. Goldenberg BA, Rawsthorne P, Bernstein CN. The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease. Am J Gastroenterol 2004; 99: 1744-1748.
12. Hindorf U, Lyrenäs E, Nilsson A, Schmiegelow K. Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease. Scand J Gastroenterol 2004; 39: 1105-1112.
13. Belaiche J, Desager JP, Horsmans Y, Louis E. Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease. Scand J Gastroenterol 2001; 36: 71-76.
14. Wright S, Sanders DS, Lobo AJ, Lennard L. Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease. Gut 2004; 53: 1123-1128.
15. Dubinsky MC, Yang H, Hassard PV, Seidman EG, Kam LY, Abreu MT et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002; 122: 904-915.
16. Lowry PW, Franklin CL, Weaver AL, Pike MG, Mays DC, Tremaine WJ et al. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 2001; 49: 665-670.
17. Osterman MT, Kundu R, Lichtenstein GR, Lewis JD. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 2006; 130: 1047-1053.
18. Stocco G, Londero M, Campanozzi A, Martelossi S, Marino S, Malusa N et al. Usefulness of the measurement of azathioprine metabolites in the assessment of non-adherence. J Crohns Colitis 2010; 4: 599-602.
19. Sparrow MP, Hande SA, Friedman S, Lim WC, Reddy SI, Cao D et al. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther 2005; 22: 441-446.
20. Gardiner SJ, Gearry RB, Burt MJ, Chalmers-Watson T, Chapman BA, Ross AG et al. Allopurinol might improve response to azathioprine and 6-mercaptopurine by correcting an unfavorable metabolite ratio. J Gastroenterol Hepatol 2011; 26: 49-54.
21. Sparrow MP. IBD: switching metabolism - can two drugs be better than one? Nat Rev Gastroenterol Hepatol 2010; 7: 420-422.
22. Leong RW, Gearry RB, Sparrow MP. Thiopurine hepatotoxicity in inflammatory bowel disease: the role for adding allopurinol. Expert Opin Drug Saf 2008; 7: 607-616.
23. Ansari A, Patel N, Sanderson J, O'Donohue J, Duley JA, Florin THJ. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2010; 31: 640-647.
24. Ansari A, Elliott T, Baburajan B, Mayhead P, O'Donohue J, Chocair P et al. Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. Aliment Pharmacol Ther 2008; 28: 734-741.
25. Witte TN, Ginsberg AL. Use of allopurinol with low-dose 6-mercaptopurine in inflammatory bowel disease to achieve optimal active metabolite levels: a review of four cases and the literature. Can J Gastroenterol 2008; 22: 181-185.
26. Gerich ME, Quiros JA, Marcin JP, Tennyson L, Henthorn M, Prindiville TP. A prospective evaluation of the impact of allopurinol in pediatric and adult IBD patients with preferential metabolism of 6-mercaptopurine to 6-methylmercaptopurine. J Crohns Colitis 2010; 4: 546-552.
27. Leung Y, Sparrow MP, Schwartz M, Hanauer SB. Long term efficacy and safety of allopurinol and azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease. J Crohns Colitis 2009; 3: 162-167.
28. Rahhal RM, Bishop WP. Initial clinical experience with allopurinol-thiopurine combination therapy in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2008; 14: 1678-1682.
29. Gearry RB, Barclay ML, Roberts RL, Harraway J, Zhang M, Pike LS et al. Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice. Intern Med J 2005; 35: 580-585.
30. Haines ML, Ajlouni Y, Irving PM, Sparrow MP, Rose R, Gearry RB et al. Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease. Inflamm Bowel Dis 2011; 17: 1301-1307.
31. Roblin X, Oussalah A, Chevaux J-B, Sparrow M, Peyrin-Biroulet L. Use of thiopurine testing in the management of inflammatory bowel diseases in clinical practice: a worldwide survey of experts. Inflamm Bowel Dis 2011; 17: 2480-2487.
32. Siriwardana A, Koo J, Ng W, Connor S. Azathioprine, 6-mercaptopurine and thiopurine s-methyltransferase levels in inflammatory bowel disease: what is current clinical practice? J Gastroenterol Hepatol 2009; 24(s2): A311-312.
33. González-Lama Y, Bermejo F, López-Sanromán A, García-Sánchez V, Esteve M, Cabriada JL et al. Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients. Aliment Pharmacol Ther 2011; 34: 544-554.
34. Gearry RB, Day AS, Barclay ML, Leong RWL, Sparrow MP. Azathioprine and allopurinol: a two-edged interaction. J Gastroenterol Hepatol 2010; 25: 653-655.
35. Dassopoulos T, Martin CF, Galanko J, Wolf DC, Dubinsky M, Sandler RS et al. T1192 a randomized trial of metabolite-adjusted versus weight-based dosing of azathioprine (AZA) in Crohn's disease (CD). [clinicaltrials.Gov identifier Nct00113503]. Gastroenterology 2009; 136: A-519.
36. Hindorf U, Jahed K, Bergquist A, Verbaan H, Prytz H, Wallerstedt S et al. Characterisation and utility of thiopurine methyltransferase and thiopurine metabolite measurements in autoimmune hepatitis. J Hepatol 2010; 52: 106-111.
37. Shemesh E. Non-adherence to medications following pediatric liver transplantation. Pediatr Transplant 2004; 8: 600-605.
38. El-Azhary RA, Farmer SA, Drage LA, Rogers RS, McEvoy MT, Davis MDP et al. Thioguanine nucleotides and thiopurine methyltransferase in immunobullous diseases: optimal levels as adjunctive tools for azathioprine monitoring. Arch Dermatol 2009; 145: 644-652.
39. Askanase AD, Wallace DJ, Weisman MH, Tseng C-E, Bernstein L, Belmont HM et al. Use of pharmacogenetics, enzymatic phenotyping, and metabolite monitoring to guide treatment with azathioprine in patients with systemic lupus erythematosus. J Rheumatol 2009; 36: 89-95.